Stock_Titan
Posted - 5 days ago
$PROF Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
https://www.stocktitan.net/news/PROF/profound-medical-to-release-first-quarter-2024-financial-results-on-z42myt34topd.html
Stock_Titan
Posted - 2 weeks ago
$PROF Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
https://www.stocktitan.net/news/PROF/profound-medical-to-participate-in-the-2024-bloom-burton-co-rznaem4s6cpi.html
TickerDD_com
Posted - 1 month ago
From 3/8/2024, looking back across 22 Month-Ends for PROF, Percentage Change of Average Monthly Price had More Positives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $PROF #PROF #PROFStock #TickerDD https://www.youtube.com/watch?v=hWQXiLAXCFg
unnconscious
Posted - 1 month ago
$PROF earnings call wasn't great. It sounds like they might run out of cash again by 2025 when they get the codes so there might be a better opportunity long term later in the year.
The CEO is so boring it's hard to listen to but they seem reliable, they don't over promise and they set expectations low or not at all and don't raise more monet than they can justify.
The stock should recover by next week though so i won't sell my earnings position until its back up.
epsguid
Posted - 1 month ago
$PROF reported a loss of $0.42, consensus was ($0.28) via @eWhispers #epsmiss http://eps.sh/d/prof
Stock_Titan
Posted - 1 month ago
$PROF Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
https://www.stocktitan.net/news/PROF/profound-medical-announces-fourth-quarter-and-full-year-2023-yl1qhugg2fc3.html
unnconscious
Posted - 1 month ago
$PROF bought 2.5k shares for the earnings, hopefully they will give some foreword expectations for the Siemens deal or just in general for the ramp up in sales when they get the CPT code in less than a year.
Stock_Titan
Posted - 1 month ago
$PROF Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
https://www.stocktitan.net/news/PROF/profound-medical-to-participate-in-barclays-26th-annual-global-ueztm81oxjuh.html
unnconscious
Posted - 1 month ago
$PROF I had waited a long time for them to raise money. Now that they have, i think its a great time to buy. Normally I just trade and don't invest, but I'll be buying shares longer term for their earnings in march. When they get the code next January revenues could ramp very fast.
Stock_Titan
Posted - 2 months ago
$PROF Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
https://www.stocktitan.net/news/PROF/profound-medical-in-collaboration-with-siemens-healthineers-to-tu8vvxgs1o7n.html
Stock_Titan
Posted - 2 months ago
$PROF Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
https://www.stocktitan.net/news/PROF/profound-medical-to-release-fourth-quarter-and-full-year-2023-vnzkwg7ikivm.html
GrantDiaz
Posted - 2 months ago
$PROF I'm in this for 6,000 shares so far. Anybody on this board?
StockAutomatePro
Posted - 3 months ago
$PROF Stock is headed for a rally according to the chart. We alerted the BUY signal at $7.45 and we were able to close this one with profit at $7.85 💯 See more details at StockAutomate.com
DonCorleone77
Posted - 3 months ago
$PROF Profound Medical to sell 391,667 shares at $7.50 in private placement Profound Medical announced that the company has entered into subscription agreements, dated as of January 16, with certain existing Canadian institutional investors, in connection with a non-brokered private placement for aggregate gross proceeds of approximately $2,937,502. In connection with the closing of the private placement, the company is expected to issue an aggregate of 391,667 common shares in the capital of the company at a price of $7.50 per common share. All of the common shares issued in connection with the private placement will be subject to a four-month and one day statutory hold period. The company expects to use the proceeds from the closing to fund the continued commercialization of the TULSA-PRO system in the United States, the continued development and commercialization of the TULSA-PRO system and the Sonalleve system globally and for working capital and general corporate purposes....
tickeron
Posted - 3 months ago
If you have $PHB or $PHD or $PROF in your portfolio, pay attention! https://srnk.us/go/4970592
tickeron
Posted - 3 months ago
What are the most profitable stocks right now? Pick the best $PHB vs. $PHD vs. $PROF. https://srnk.us/go/4969654
midnite_clyde
Posted - 3 months ago
$PROF Austin was admitted to Walter Reed National Military Medical Center and underwent minimally invasive surgical procedure to treat and cure prostate cancer. Austin was under general anesthesia during the procedure. The next day, Austin was discharged and went home. However, on Jan. 1, Austin was admitted again with complications from the Dec. 22 procedure determined to be a urinary tract infection.
tickeron
Posted - 3 months ago
How does this make you feel? $PROF Aroon Indicator entered a Downtrend. View odds of downtrend. https://srnk.us/go/4962319
unnconscious
Posted - 3 months ago
$PROF I've been waiting at least 6 months for them to raise money, hopefully it gets really low because I'd like to buy some this year.
NetworkNewsWire
Posted - 3 months ago
BioMedNewsBreaks – $PRN.TO $PROF Announces Pricing of US$20M Public Offering https://ibn.fm/iiBou
EarningsInsider
Posted - 3 months ago
$PROF updates FY 2023 guidance to EPS and revenue guidance to $7.1 million-$7.2 million. www.marketbeat.com/stocks/NASDAQ/PROF/earnings/
EarningsInsider
Posted - 3 months ago
$PROF updates Q4 2023 guidance to EPS and revenue guidance to $1.9 million-$2.0 million. www.marketbeat.com/stocks/NASDAQ/PROF/earnings/
DonCorleone77
Posted - 3 months ago
$PROF 2 of 2 - Profound Medical sees FY23 revenue $7.1M-$7.2M, consensus $7.22M ....The growth capital raised through our recent financing, which closed yesterday, puts us in a stronger position to make the requisite investments, particularly in our commercial organization, to maximize the exciting opportunity for TULSA that we see ahead. In preparation for the permanent CPT(R) Category 1 codes for TULSA going into effect at the beginning of 2025 -- an anticipated major revenue inflection point for our business - our top priorities for 2024 will be to further increase our TULSA-PRO(R) installed base, support increased system utilization, complete our ongoing Level 1 CAPTAIN trial comparing the TULSA procedure to radical prostatectomy for the treatment of prostate cancer, and advance additional TULSA AI modules designed to increase both the ease and speed of prostate disease treatment. We look forward to updating investors as we progress."
DonCorleone77
Posted - 3 months ago
$PROF 1 of 2 - Profound Medical sees FY23 revenue $7.1M-$7.2M, consensus $7.22M The company said, "For the full year 2023, Profound anticipates total revenues to be in the approximate range of $7.1 million to $7.2 million. These figures are preliminary and unaudited, and actual revenues may differ." "Our focus on early adopters and teaching hospitals resulted in the adoption of TULSA-PRO(R) continuing to increase throughout 2023, both in terms of installed base growth and existing system utilization," said Arun Menawat, Profound's CEO and Chairman. "Q4-2023 marked the seventh consecutive quarter of recurring revenue growth; and TULSA-PRO(R) is now installed at, or contracted with, 10 of the top 20 cancer hospitals in the United States as ranked by U.S. News and World Report, including prestigious institutions such as MD Anderson, Mayo Clinic-Rochester, UCLA Medical Center, Brigham and Women's Hospital, Johns Hopkins Hospital, and Cleveland Clinic, among others....
DonCorleone77
Posted - 3 months ago
$PROF Profound Medical reports preliminary Q4 revenue $1.9M-$2M, consensus $2.37M The company said, "Profound anticipates total revenues for the fourth quarter of 2023 to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO(R) consumables, lease of medical devices, procedures and services associated with extended warranties. This represents recurring revenue growth of between 51% and 59% year-over-year, and between 10% and 16% sequentially over the 2023 third quarter."
Stock_Titan
Posted - 3 months ago
$PROF Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
https://www.stocktitan.net/news/PROF/profound-medical-announces-preliminary-unaudited-fourth-quarter-and-a72221yjv7cr.html
tickeron
Posted - 12/29/23
This is amazing! What do you think? $PROF Stochastic Oscillator left the oversold zone. View odds of downtrend. https://srnk.us/go/4954466
OpenOutcrier
Posted - 3 months ago
$PROF (-8.6% pre) Profound Medical (PROF) Announces Proposed Public Offering of Common Shares - SI https://ooc.bz/l/20809
